Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the

­ Promising data from ongoing clinical trials of neoantigen cancer vaccine TG4050 and HPV-positive cancer therapeutic vaccine TG4001 presented at key congresses in H1 2023­ Immunogenicity clinical data from ongoing trials confirm mechanism of action of Transgene’s therapeutic vaccines TG4050 and TG4001­ Transgene pl...

Related Keywords

France ,United Kingdom ,United States ,Lucie Larguier ,Christian Ottensmeier ,Ben Brahim ,Johnc Bell ,Carol Stuckley ,Transgene Euronext ,Alessandro Riva ,Pedro Romero ,Twitter ,Corporate Communications ,Jolla Institute For Immunology ,Astrazeneca ,University Of Lausanne ,Merck Co ,Company Board Of Directors ,University Of Liverpool ,Chief Executive Officer ,Regulatory News ,Euronext Paris ,Professor Christian Ottensmeier ,European Journal ,Phasei Delivir ,Combined General Meeting ,Statutory Auditors ,Tasly Biopharmaceuticals ,Artificial Intelligence ,Risk Factors ,Universal Registration Document ,